Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7963983 | 0.79 | DRD2 (0.46) | DRD2DRD3HTR2AHTR1AHRH1 | |
| SCHEMBL136221 | 0.79 | DRD2 (0.50) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL10746746 | 0.79 | HTR2C (0.47) | DRD2DRD3HTR2AHTR1AHRH1 | |
| SCHEMBL27678979 | 0.79 | DRD2 (0.54) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL2787499 | 0.79 | HTR1A (0.47) | DRD2DRD3HTR2AHTR1AHRH1 | |
| SCHEMBL30752424 | 0.79 | DRD2 (0.46) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL1639063 | 0.79 | DRD2 (0.46) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL28432438 | 0.79 | DRD2 (0.43) | DRD2DRD3HTR2AHTR1AHRH1 | |
| Hydrochloric Acid SCHEMBL31444421 | 0.78 | DRD2 (0.45) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL1538935 | 0.77 | DRD2 (0.52) | DRD2DRD3HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | claimed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | claimed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | claimed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | claimed |
| EP-4363421-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-02 | — | — | US | disclosed |
| WO-2024017880-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-01-25 | — | — | WO | disclosed |
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-12-14 | — | — | US | disclosed |
| EP-4259631-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4240742-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-08-31 | — | — | US | disclosed |
| CN-110769821-B | Spiro indolines as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008047109-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1881827-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2006114606-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL23R, IL2 | DRD2 2385/4885DRD3 1644/4885HTR2A 4341/4885 |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL2, IL23R | DRD2 2223/4885DRD3 1474/4885HTR2A 4404/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | DRD2 4360/4885DRD3 4318/4885HTR2A 1998/4885 |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | IL17A, IL15, IL2 | DRD2 3143/4885DRD3 2360/4885HTR2A 2344/4885 |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | DRD2 1707/4885DRD3 1869/4885HTR2A 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.